Company Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides.
The company’s product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.
Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Nadav Kidron |
Contact Details
Address: 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 United States | |
| Phone | 844 967 2633 |
| Website | oramed.com |
Stock Details
| Ticker Symbol | ORMP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001176309 |
| CUSIP Number | 68403P203 |
| ISIN Number | US68403P2039 |
| Employer ID | 98-0376008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nadav Kidron Esq. | President, Chief Executive Officer and Executive Chairman |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer and Director |
| Avraham Gabay | Chief Financial Officer, Treasurer and Secretary |
| Joshua Hexter | Chief Operating and Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2024 | 8-K | Current Report |
| Oct 8, 2024 | 8-K | Current Report |
| Sep 26, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Sep 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 2, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 24, 2024 | 8-K | Current Report |
| Jun 20, 2024 | ARS | Filing |